Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary ... - Markets Insider
TransCon CNP demonstrated superior annualized growth velocity (AGV) to placebo in children with achondroplasia, with LS mean treatment differences of 1.49 cm/year at Week 52 (p<0.0001) for ages 2-11 and 1.78 cm/year for ages 5-11 (p<0.0001). TransCon CNP was well-tolerated, with low frequency of mild injection site reactions. Ascendis plans to submit a New Drug Application (NDA) for TransCon CNP in Q1 2025.
Reference News
TransCon CNP demonstrated superior annualized growth velocity (AGV) to placebo in children with achondroplasia, with LS mean treatment differences of 1.49 cm/year at Week 52 (p<0.0001) for ages 2-11 and 1.78 cm/year for ages 5-11 (p<0.0001). TransCon CNP was well-tolerated, with low frequency of mild injection site reactions. Ascendis plans to submit a New Drug Application (NDA) for TransCon CNP in Q1 2025.